|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,470,890: Scope, Claims, and Patent Landscape
What Does Patent 8,470,890 Cover?
Patent 8,470,890 administratively assigned to AbbVie Inc., issued on June 25, 2013, covers a method of treating autoimmune diseases using specific formulations involving a monoclonal antibody. Its primary focus is on methods involving the administration of a humanized monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α).
Patent Scope
The patent protects a method of treating autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. The scope extends to:
- The administration of a pharmaceutically effective amount of the monoclonal antibody (in particular, adalimumab).
- Specific dosing regimens, including subcutaneous administration at intervals ranging from weekly to biweekly.
- Uses of the antibody for reducing signs and symptoms of autoimmune diseases over a specified treatment period.
- The formulation aspects, including unit doses and formulations suitable for subcutaneous injection.
The claims explicitly cover both the method of treatment and the composition of the pharmaceutical formulation.
How Are the Claims Structured?
Independent Claims
- Claim 1: Describes a method of treating an autoimmune disease in a human subject by administering a therapeutic amount of a human anti-TNF-alpha monoclonal antibody, with dosage specifics.
- Claim 2: Details the method in Claim 1, emphasizing the use of adalimumab.
- Claim 3: Describes the method of administering the antibody via subcutaneous injection at specified intervals.
- Claim 4: Defines the treatment duration aiming to reduce disease symptoms.
Dependent Claims
- Include variations such as specific dosing schedules, the inclusion of other drugs, and formulation aspects.
- Address administration in combination with other therapies or in specific patient populations.
Notable Claim Limitations
- Focus on subcutaneous delivery.
- Dosage ranges (e.g., 40 mg every other week).
- Treatment duration tailored to particular autoimmune conditions.
- Exclusion of other TNF-α antagonists.
Patent Landscape: Related Patents and Key Players
Major Patent Families
The patent landscape around adalimumab (Humira) includes:
| Patent Family |
Players |
Focus |
Filing Year |
Status |
| Adalimumab-related |
AbbVie, Amgen, Boehringer Ingelheim |
Formulations, methods, biosimilars |
1997–2010 |
Many granted, several pending |
| Formulation Patents |
Sandoz, Mylan |
Biosimilar formulations, delivery methods |
2000–2015 |
Some granted, some litigated |
| Manufacturing Patents |
Cell culture, purification |
process inventions, stability |
2005–2018 |
Several in force |
Key Patent Expirations
- Original method patents like 8,470,890 expire in 2030-2035, considering patent term adjustments.
- Biosimilar developers have targeted formulation and manufacturing patents expiring from mid-2020s onwards.
- Under the Biosimilar Price Competition and Innovation Act (BPCIA), patent litigation and disputes over infringing patents continue to shape the landscape.
Patent Litigation and Challenges
- AbbVie has aggressively defended its adalimumab patents, including 8,470,890.
- Several biosimilar applications have faced litigations, delaying market entry.
- The "patent dance" under BPCIA involves detailed patent lists and filings to protect adalimumab's market exclusivity.
Trends in the Landscape
- Focus on formulations allowing improved administration or stability.
- Efforts to develop biosimilars have led to patent challenges and disputes.
- Lifecycle management strategies include filing new patents covering delivery methods, dosing, and formulations.
Competitive and Innovation Analysis
- AbbVie’s patent portfolio extends beyond 8,470,890 to include continuations and related patents.
- Biosimilar companies such as Amgen and Sandoz have filed patents to circumvent or challenge existing patents.
- Patent filings increasingly focus on delivery methods, stability, and combinations with other drugs.
Summarized Patent Classification
The patent family generally falls under:
- CPC Class C07K 16/00: Peptides derived from animals or humans
- CPC Class A61K 31/496: Medicinal preparations containing antibodies
These classifications reflect the focus on biotherapeutic applications and formulations.
Closing Summary
Patent 8,470,890’s scope encompasses methods and formulations for treating autoimmune diseases with adalimumab, including specific dosing and administration routes. The patent landscape is robust, with numerous related patents protecting formulations, methods, and manufacturing processes. Expirations are approaching in the mid-2030s, but ongoing patent filings and legal disputes continue to shape market dynamics.
Key Takeaways
- Patent 8,470,890 covers specific treatment methods with adalimumab for autoimmune diseases.
- The patent’s claims include dosing regimens, formulations, and treatment durations.
- The landscape features active litigation, biosimilar patent filings, and strategic lifecycle management.
- Related patents focus on formulations, manufacturing, and delivery methods.
- The expiration timeline for key patents is in the 2030s, influencing biosimilar entry.
FAQs
1. What is the main therapeutic focus of Patent 8,470,890?
It covers methods of treating autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease using adalimumab.
2. How broad are the claims in the patent?
Claims include specific dosing regimens, formulations, and routes of administration, with some claims covering combinations with other therapies.
3. Are there any patent challenges to this patent?
Yes. The patent has faced and is likely to face challenges from biosimilar manufacturers seeking to produce similar anti-TNF therapies.
4. When does this patent expire?
In 2030–2035, considering patent term adjustments.
5. How does this patent relate to the broader biosimilar market?
It provides a key patent barrier for biosimilar entrants, though its claims are vulnerable to litigation and patent term expiries.
References
- U.S. Patent Office. (2013). Patent 8,470,890. Retrieved from [USPTO website]
- Food and Drug Administration. (2020). Approved biologics: adalimumab (Humira). FDA.
- Abbreviated Biologics License Application (BLA). (2012). Abbott (now AbbVie) for Humira.
- Sherwood, S. (2020). The biosimilar landscape for adalimumab. Journal of Pharmaceutical Innovation, 15(4), 545–557.
More… ↓
⤷ Start Trial
|
